United Therapeutics presented data at CHEST 2026 showing ralinepag reduced clinical worsening risk in PAH and nebulized treprostinil reduced disease progression in IPF. FDA has accepted NDAs for both drugs.
PHINDER interim analysis showed higher mortality risk scores in ILD patients with PH
DeciPHer-ILD registry baseline data showed advanced disease in PH-ILD patients
FDA has accepted NDA for ralinepag (PAH) and sNDA for nebulized treprostinil (IPF)
Presentations at CHEST 2026 Annual Meeting, October 18-21 in Phoenix
FREE ACCOUNT · NO CARD
The headline and the read are open. The reasons are one free account away, on every story.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
WHY IT MATTERS••••••••••Market transmission and exposed assetsBULL / BEAR CASE•••• / ••••Competing evidence, edited togetherNEWS ON PRICE••.•% reactionConfirmation versus SPY and sectorWHAT TO WATCH•• catalystsThe facts that can change the read
BORSAPLUSWhy it matters · Bull and bear case · Reaction against SPY and the sector · What to watch
